Comparative study to evaluate skin irritation and adhesion of Estradot^® and Climara^® in healthy postmenopausal women

References

• Ginsburg J, Hardiman P, Okolo S. Hormone replacement therapy in general practice. Br Med J 1991;302:1601–2
   Google Scholar
• Birkhaiiser MH, Haenggi W. Benefits of different routes of administration. Int J Fertil Menopausal Stud 1994;39(Suppl 1):11–19
   Google Scholar
• Grodstein F, Stampfer, MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769–75
   PubMed Web of Science ®Google Scholar
• Insogna K, Concato J, Henrich J. Boning up on estrogen: new options, new concerns. J Am Med Assoc 1996;276:1430–2
   Google Scholar
• Kiel DP, Felson DT, Anderson JJ, et al. Hip frac-ture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med 1987;317:1169–74
   PubMed Web of Science ®Google Scholar
• Schairer C, Adami HO, Hoover R, Persson I. Cause-specific mortality in women receiving hormone replacement therapy. Epidemiology 1997;8:59–65
   PubMed Web of Science ®Google Scholar
• Archer DF, Furst K, Tipping D, et al. A random-ized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. Obstet Gynecol 1999;94:498–503
   PubMed Web of Science ®Google Scholar
• Cooper C, Stakkestad JA, Radowicki S, et al. Matrix delivery transdermal 17[3-estradiol for the prevention of bone loss in postmenopausal women. The International Study Group. Osteo-porosis Int 1999;9:358–66
   PubMed Web of Science ®Google Scholar
• Kuhl IL. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990;12:171–97
   PubMed Web of Science ®Google Scholar
• Aedo AR, Landgren BM, Diczfalusy E. Pharmacokinetics and biotransformation of orally administerd oestrone sulphate and oestra-diol valerate in post-menopausal women. Maturitas 1990;12:333–43
   Google Scholar
• Balfour JA, McTavish D. Transdermal estradiol. A review of its pharmacological profile, and therapeutic potential in the prevention of post-menopausal osteoporosis. Drugs Aging 1992;2: 487–507
   Google Scholar
• Samsioe G. Hormone replacement therapy: expanding treatment options with transdermal delivery. Curr Tber Res Clin Exp 1999;60:161–7
   Web of Science ®Google Scholar
• Li C, Samsioe G, Wilaman K, et al. Effects of norethisterone acetate addition to estradiol in long term HRT. Maturitas 2000;36:139–52
   PubMed Web of Science ®Google Scholar
• Notelovitz M, Bachman GA, Lucking D. Evalua-tion of Menorest at dose strengths 37.5,50,75, 100µg/day. Eur J Clin Res 1996;8: 219–34
   Google Scholar
• Studd JWW, McCarthy K, Zamblera D, et al. Efficacy and tolerance of Menorest compared to Premarin in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study. Maturitas 1995;22: 105–14
   Google Scholar
• Studd JWW, McCarthy K, Zamblera D, et al. A double-blind, double-dummy, comparative study of Menorest 50® versus Premarin® 0.625 mg in the treatment of menopausal symptoms and the prevention of bone loss in patients with meno-pausal symptoms. Clin Drug Invest 1996;11: 205–13
   Google Scholar
• Pornel B, Genazzani AR, Costes D, et al. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of post-menopausal symptoms. A randomised, multi-center, parallel group study. Maturitas 1995;22: 207–18
   Google Scholar
• Sefaty D, Caulin F. Efficacy and tolerability of transdermal 17[3-estradiol in patients with climacteric symptoms: dose titration according to individual choice. Curr Tber Res Clin Exp 1996;57:506–15
   Web of Science ®Google Scholar
• Studd J, Panay N, Zamblera D, Leather AT. HRT and long-term compliance: the efficacy and safety of Menorest. Int J Gynecol Obstet 1996;52 (Suppl 1):S21–5
   PubMedGoogle Scholar
• Liibbert H, Nauert C. Continuous versus cyclical transdermal estrogen replacement therapy in post-menopausal women: influence on climac-teric symptoms, body weight and bleeding pattern. Maturitas 1997;28:117–25
   PubMed Web of Science ®Google Scholar
• Cooper C, Stakkestad JA, Radowicki S, et al. Matrix delivery transdermal 170-estradiol for the prevention of bone loss in postmenopausal women. Osteoporosis Int 1999;9:358–66
   PubMed Web of Science ®Google Scholar
• Delmas PD, Pornel B, Felsenberg D, et al. A dose-ranging trial of a matrix transdermal 170-estradiol for the prevention of bone loss in early postmenopausal women. Bone 1999;24: 517–23
   PubMed Web of Science ®Google Scholar
• Andersson TL, Stehle B, Davidson B, Hoglund P. Drug concentration effect relationship of estradiol from two matrix transdermal delivery systems: Menorest® and Climara. Maturitas 2000;35:245–52
   PubMed Web of Science ®Google Scholar
• Andersson TL, Stehle B, Davidson B, Hoglund P. Bioavailability of estradiol from two matrix delivery systems: Menorest and Climara. Maturitas 2000;34:57–64
   PubMed Web of Science ®Google Scholar
• Novartis Pharma AG. A bioavailability study of two doses of Noven second generation estradiol transdermal system in healthy post-menopausal women. Report on Protocol 1012, Novartis Pharma AG, Basel, January 1997
   Google Scholar
• Novartis Pharma AG. A multiple dose steady state bioequivalence study of two estradiol transdermal systems in healthy post-menopausal women. Report on Protocol 004. Novartis Pharma AG, Basel, March 1998
   Google Scholar